Topic
Topic
REZOLVE-AA topline data show rezpegaldesleukin produces durable hair regrowth in alopecia areata, per Dermatology Times — a sustained-response signal pointing toward long-term disease modification.
A JAAD study published October 8, 2026 defines post-regrowth hair texture change in alopecia areata as a distinct clinical and ul…
Nektar says REZPEG produced durable hair regrowth in alopecia patients, and the data set up a Phase III trial of the candidate in…
New rezpegaldesleukin data presented at EADV Congress 2026 support long-term durability and disease improvement in both alopecia…
Rezpegaldesleukin delivered durable hair regrowth in the REZOLVE-AA alopecia areata trial, strengthening the case for selective I…
New rezpegaldesleukin data supporting long-term durability and disease improvement in alopecia areata and atopic dermatitis will…
Eighty-four of 127 items reached consensus in a 50-expert Delphi on pediatric oral minoxidil; a 60-week study shows RCM inflammat…
A cross-sectional analysis published October 8, 2026 in JAAD audits pediatric enrollment and demographic reporting across alopeci…
A Frontiers case report documents long-term upadacitinib therapy in one patient with atopic dermatitis, bullous pemphigoid and al…
Alopecia Areata Awareness Month returns in 2026 as dermatology takes stock of a year in which visibility, patient advocacy and cl…